financetom
Business
financetom
/
Business
/
Beijing E-Town sues US firm Applied Materials alleging trade secrets leak
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Beijing E-Town sues US firm Applied Materials alleging trade secrets leak
Aug 13, 2025 8:15 AM

BEIJING, Aug 13 (Reuters) - Beijing E-Town Semiconductor

Technologies, a semiconductor equipment firm backed

by Beijing's government, on Wednesday said it has sued U.S. chip

equipment supplier Applied Materials ( AMAT ) over alleged trade

secrets infringement.

Applied Materials ( AMAT ) had illegally obtained and used Beijing

E-Town's core technology secrets related to plasma sources and

wafer surface treatment, the Beijing-based company said

according to a filing on the Shanghai Stock Exchange.

The company, which is seeking 99.99 million yuan ($13.94

million) in compensation, alleged that Applied Materials ( AMAT ) had

disclosed technical secrets by applying for a patent in China

and claiming the patent's application rights.

Applied Materials ( AMAT ) did not immediately respond to a request

for comment.

In 2016, Beijing E-Town acquired Mattson Technology, a

California-based semiconductor wafer processing equipment

designer and manufacturer.

Applied Materials ( AMAT ) sued Mattson in 2022, alleging that it had

hired its former employees with the intention of stealing trade

secrets. In 2023, Mattson countersued Applied Materials ( AMAT ) making

similar accusations.

In the new case filed with the Beijing Intellectual Property

Court, Beijing E-Town alleged that Applied Materials ( AMAT ) had hired

two former Mattson employees, who were later listed as the

principal inventors behind a patent filed by Applied Materials ( AMAT )

in China.

The patent, filed with China's intellectual property

administration, disclosed confidential technical know-how

jointly held by Beijing E-Town and Mattson, Beijing E-Town said.

Applied Materials' ( AMAT ) actions, the Beijing firm said, violated

China's fair competition law and constituted infringement of its

trade secrets.

The Beijing court has accepted the civil case but no court

hearing has yet been held, Beijing E-Town said.

($1 = 7.1746 Chinese yuan renminbi)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Oklo Selected For Three Projects Under DOE's Reactor Pilot Program
Oklo Selected For Three Projects Under DOE's Reactor Pilot Program
Aug 13, 2025
Oklo Inc. ( OKLO ) shares are trading higher on Wednesday. The firm and its subsidiary Atomic Alchemy have been chosen for three projects under the U.S. Department of Energy's new Reactor Pilot Program. The advanced nuclear developer secured two project slots, while its isotope production arm claimed one, aiming to fast-track the demonstration of test reactors in the U.S....
Creative Medical Says FDA Grants Fast Track Designation to its Lead Investigational Therapy for Chronic Lower Back Pain
Creative Medical Says FDA Grants Fast Track Designation to its Lead Investigational Therapy for Chronic Lower Back Pain
Aug 13, 2025
10:42 AM EDT, 08/13/2025 (MT Newswires) -- Creative Medical Technology ( CELZ ) said Wednesday the US Food and Drug Administration has granted fast track designation to its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease, a major cause of chronic lower back pain and disability. The designation enables the company to benefit from quicker FDA interactions,...
CEL-SCI Says Breakthrough Medicine Designation Application Filed in Saudi Arabia for Cancer Immunotherapy
CEL-SCI Says Breakthrough Medicine Designation Application Filed in Saudi Arabia for Cancer Immunotherapy
Aug 13, 2025
10:43 AM EDT, 08/13/2025 (MT Newswires) -- CEL-SCI ( CVM ) said Wednesday a breakthrough medicine designation application has been filed for head and neck cancer immunotherapy Multikine by an undisclosed Saudi Arabian pharmaceutical firm with the Saudi Food and Drug Authority. CEL-SCI ( CVM ) signed a memorandum of understanding with the Saudi Arabian firm for the commercialization of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved